#214168

Star Therapeutics Announces $200 Million Private Financing to Advance Pipeline of Best-in-Disease Therapies

SOUTH SAN FRANCISCO, CA, October 23, 2026 – Star Therapeutics, a biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced a $200 million private financing. The financing follows the July 2026 acquisition of Star subsidiary...

By |2026-10-23T06:50:41-05:00October 23, 2026|Press Release|0 Comments
Read More

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

WILMINGTON, DE, July 6, 2026 – Incyte (Nasdaq:INCY) announced today it has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD)...

By |2026-11-02T16:24:07-06:00July 6, 2026|Press Release|0 Comments
Read More

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

WILMINGTON, DE, June 8, 2026 – Incyte (Nasdaq:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales milestones...

By |2026-11-02T16:23:13-06:00June 8, 2026|Press Release|0 Comments
Read More

THANK YOU

We look forward to connecting with you